Prognostic serum biomarkers in cancer patients with COVID-19: A systematic review

Lee, Te-An; Wang, Shih-Han; Kuo, Chun‐Tse; Li, Chia-Wei; McCullough, Louise D.; Bello, Dhimiter; Lai, Yun‐Ju

doi:10.1016/j.tranon.2022.101443

Cited by 5 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The quality of the studies was assessed using the modified REporting recommendations for tumor MARKers prognostic studies (REMARK), which provides a valuable reference when reporting or analyzing medical studies related to diseases markers or prognostic markers (12,15,16). Two independent reviewers (S-HL and T-AL) verified the total scores.…”

Section: Quality Assessmentmentioning

confidence: 99%

“…For example, the up-regulated levels of neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP) in serum may indicate neuronal damage in the progression of neurodegenerative diseases, such as Alzheimer's disease (10) or Parkinson's disease (11). In addition, Interleukin (IL) 6 was not only identified as a prognostic biomarker for disease monitoring in cancer patients with severe COVID-19 (12) but also served as a target for treating COVID-19-related systemic inflammation, such as acute respiratory distress syndrome and cytokine release syndrome (13,14). While the literature on this topic is evolving fast, to-date diagnostic biomarkers for long COVID remain unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in long COVID-19: A systematic review

et al. 2023

Self Cite

View full text Add to dashboard Cite

PurposeLong COVID, also known as post-acute sequelae of COVID-19, refers to the constellation of long-term symptoms experienced by people suffering persistent symptoms for one or more months after SARS-CoV-2 infection. Blood biomarkers can be altered in long COVID patients; however, biomarkers associated with long COVID symptoms and their roles in disease progression remain undetermined. This study aims to systematically evaluate blood biomarkers that may act as indicators or therapeutic targets for long COVID.MethodsA systematic literature review in PubMed, Embase, and CINAHL was performed on 18 August 2022. The search keywords long COVID-19 symptoms and biomarkers were used to filter out the eligible studies, which were then carefully evaluated.ResultsIdentified from 28 studies and representing six biological classifications, 113 biomarkers were significantly associated with long COVID: (1) Cytokine/Chemokine (38, 33.6%); (2) Biochemical markers (24, 21.2%); (3) Vascular markers (20, 17.7%); (4) Neurological markers (6, 5.3%); (5) Acute phase protein (5, 4.4%); and (6) Others (20, 17.7%). Compared with healthy control or recovered patients without long COVID symptoms, 79 biomarkers were increased, 29 were decreased, and 5 required further determination in the long COVID patients. Of these, up-regulated Interleukin 6, C-reactive protein, and tumor necrosis factor alpha might serve as the potential diagnostic biomarkers for long COVID. Moreover, long COVID patients with neurological symptoms exhibited higher levels of neurofilament light chain and glial fibrillary acidic protein whereas those with pulmonary symptoms exhibited a higher level of transforming growth factor beta.ConclusionLong COVID patients present elevated inflammatory biomarkers after initial infection. Our study found significant associations between specific biomarkers and long COVID symptoms. Further investigations are warranted to identify a core set of blood biomarkers that can be used to diagnose and manage long COVID patients in clinical practice.

show abstract

Section: Quality Assessmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biomarkers in long COVID-19: A systematic review

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…The study population we included had different severities of illness, and the overall mortality rate was 19%. Many studies have used various biomarkers, such as CRP [ 39 – 44 ], PCT [ 39 , 43 , 45 , 46 ], IL-6 [ 39 , 43 , 46 ], WBC [ 40 , 47 – 49 ], D-dimer [ 42 , 44 , 46 , 50 , 51 ], lactate dehydrogenase (LDH) [ 39 , 42 – 44 , 46 , 47 ], N-terminal pro-B-type natriuretic peptide (NT-proBNP) [ 39 , 52 , 53 ], and Troponin T [ 39 , 54 ], and critical illness scores, such as APACHE II [ 55 – 57 ], SOFA [ 55 , 56 , 58 – 60 ], SAPS [ 61 – 64 ], and CURB65 [ 59 , 61 , 65 ], to evaluate the prognosis of patients with COVID-19. The APACHE II and SOFA scoring systems require the worst values of the clinical and biological parameters to be recorded within 24 h of admission [ 66 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating mid-regional proadrenomedullin is a predictor of mortality in patients with COVID-19: a systematic review and meta-analysis

Wang

Liu

et al. 2023

BMC Infect Dis

View full text Add to dashboard Cite

Background Although there is increasing understanding of the changes in the laboratory parameters of Coronavirus disease 2019 (COVID-19), the correlation between circulating Mid-regional Proadrenomedullin (MR-proADM) and mortality of patients with COVID-19 is not fully understood. In this study, we conducted a systematic review and meta-analysis to evaluate the prognostic value of MR-proADM in patients with COVID-19. Methods The PubMed, Embase, Web of Science, Cochrane Library, Wanfang, SinoMed and Chinese National Knowledge Infrastructure (CNKI) databases were searched from 1 January 2020 to 20 March 2022 for relevant literature. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) was used to assess quality bias, STATA was employed to pool the effect size by a random effects model, and potential publication bias and sensitivity analyses were performed. Results 14 studies comprising 1822 patients with COVID-19 met the inclusion criteria, there were 1145 (62.8%) males and 677 (31.2%) females, and the mean age was 63.8 ± 16.1 years. The concentration of MR-proADM was compared between the survivors and non-survivors in 9 studies and the difference was significant (P < 0.01), I2 = 46%. The combined sensitivity was 0.86 [0.73–0.92], and the combined specificity was 0.78 [0.68–0.86]. We drew the summary receiver operating characteristic (SROC) curve and calculated the area under curve (AUC) = 0.90 [0.87–0.92]. An increase of 1 nmol/L of MR-proADM was independently associated with a more than threefold increase in mortality (odds ratio (OR) 3.03, 95% confidence interval (CI) 2.26–4.06, I2 = 0.0%, P = 0.633). The predictive value of MR-proADM for mortality was better than many other biomarkers. Conclusion MR-proADM had a very good predictive value for the poor prognosis of COVID-19 patients. Increased levels of MR-proADM were independently associated with mortality in COVID-19 patients and may allow a better risk stratification.

show abstract

“…IL-6 and IL-2R were independent risk factors for severe events in all COVID-19 patients based on univariate analysis though multivariate analysis of IL-6 and IL-2R could not be performed due to some missing data. Studies have reported that the levels of cytokines (IL-6, IL-2R, and IFN-γ) in cancer patients with COVID-19 are significantly higher than those in noncancer patients (28,29). A retrospective cohort study of 2052 hospitalized patients with COVID-19 showed that inflammatory factors (highly sensitive CRP, procalcitonin) and cytokines (IL-2R, IL-6, IL-8) were higher in cancer patients compared with noncancer patients (30).…”

Section: Discussionmentioning

confidence: 99%

Comparison of clinical outcomes and risk factors for COVID-19 infection in cancer patients without anticancer treatment and noncancer patients

Yang

Hua-xin

Cui

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundPrevious studies have shown that cancer patients have higher rates of coronavirus disease 2019 (COVID-19) infection and mortality than noncancer patients. However, the differences between cancer patients undergoing regular follow-up without anticancer treatment and noncancer patients with COVID-19 have remained insufficiently investigated.MethodsA retrospective case–control study of 52 patients with COVID-19 infection was performed with a 1:3 matched proportion of cancer patients undergoing regular follow-up without anticancer treatment and noncancer patients. The demographic characteristics, clinical data, laboratory tests, treatment, and complications of patients were collected from medical records. Chi-square tests and univariate and multivariate regressions were performed to assess the differences between these two cohorts of COVID-19 patients with and without cancer and risk factors for severe events in COVID-19 patients.ResultsIncreased C-reactive protein (CRP) (>4 mg/L) (p = 0.015) and lactate dehydrogenase (LDH) (>243 IU/L) (p = 0.038) were identified as risk factors for severe events in all enrolled COVID-19 patients based on multivariate analysis, but cancer as a chronic disease (p = 1.000) was not identified as an independent risk factor for severe events in COVID-19 patients. Compared with noncancer patients, cancer patients had a significantly longer median hospitalization time (29 days vs. 19 days, p = 0.048) and a higher incidence of hypoalbuminemia complications (84.6 vs. 46.2%, p = 0.016).ConclusionsIncreased CRP and LDH were risk factors for severe events in all enrolled COVID-19 patients, and an increased incidence of hypoalbuminemia complications and longer hospitalization were noted in COVID-19 cancer patients undergoing regular follow-up without anticancer treatment compared with noncancer patients.

show abstract

Prognostic serum biomarkers in cancer patients with COVID-19: A systematic review

Cited by 5 publications

References 41 publications

Biomarkers in long COVID-19: A systematic review

Biomarkers in long COVID-19: A systematic review

Circulating mid-regional proadrenomedullin is a predictor of mortality in patients with COVID-19: a systematic review and meta-analysis

Comparison of clinical outcomes and risk factors for COVID-19 infection in cancer patients without anticancer treatment and noncancer patients

Contact Info

Product

Resources

About